RecruitingPhase 2NCT05554406
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Studying Acute promyelocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Paul J ShamiSWOG Cancer Research Network
- Intervention
- Azacitidine(drug)
- Enrollment
- 335 enrolled
- Eligibility
- 18-59 years · All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- UCSF Medical Center-Parnassus, San Francisco, California, United States
- Mills Health Center, San Mateo, California, United States
- Yale University, New Haven, Connecticut, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Miami Cancer Institute, Miami, Florida, United States
- Phoebe Putney Memorial Hospital, Albany, Georgia, United States
- Augusta University Medical Center, Augusta, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05554406 on ClinicalTrials.govOther trials for Acute promyelocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07563179Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaShenzhen University General Hospital
- RECRUITINGPHASE3NCT07504458Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaQuetzal Therapeutics
- RECRUITINGPHASE3NCT07223814Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)Stichting Hemato-Oncologie voor Volwassenen Nederland
- ACTIVE NOT RECRUITINGNANCT07187505Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaAnhui Medical University
- RECRUITINGPHASE3NCT07503730Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).First Affiliated Hospital Xi'an Jiaotong University
- ENROLLING BY INVITATIONNANCT06697327Daunorubicin + Cytarabine + Venetoclax in de Novo AMLAnhui Medical University
- RECRUITINGPHASE1NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AMLRichard Stone, MD
- RECRUITINGPHASE3NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLDaiichi Sankyo